Drug Profile

PMN 267

Alternative Names: PMN-267; TDP43 targeting antibody - ProMIS Neurosciences

Latest Information Update: 21 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ProMIS Neurosciences
Class Antidementias; Monoclonal antibodies
Mechanism of Action TDP-43 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Amyotrophic lateral sclerosis; Dementia; Frontotemporal dementia

Most Recent Events

12 May 2026 PMN 267 is still in preclinical development for Amyotrophic-lateral-sclerosis in Canada (Parenteral)
12 Nov 2025 ProMIS Neurosciences plans to initiate IND-enabling studies
14 Oct 2025 Preclinical trials in Dementia in Canada (Parenteral) (ProMIS Neurosciences pipeline, October 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com